Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT06421935

Ongoing Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers will also look for any signs that the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
M9466 (PARP1 inhibitor), tuvusertib, abiraterone acetate, prednisone/prednisolone
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so it is too soon to know if the drug works. The main goal is safety, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma neoplasm ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Cancer Institute Hospital of JFCR

    Kōtoku, Japan

  • Cancer Research SA

    Adelaide, Australia

  • Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica

    Madrid, Spain

  • GenesisCare North Shore (Oncology)

    St Leonards, Australia

  • Harasanshin Hospital

    Fukuoka, Japan

  • Hospital HM Nou Delfos - START Barcelona

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron - Oncology Dept.

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre - Servicio de Oncologia

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I

    Madrid, Spain

  • ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia

    Barcelona, Spain

  • NEXT Madrid - Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Spain

  • NEXT Oncology - PARENT

    New York, New York, 10065, United States

  • NHO Kumamoto Medical Center - Dept of Urology

    Kumamoto, Japan

  • National Cancer Center Hospital East - Dept of Experimental Therapeutics

    Kashiwa-shi, Japan

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases

    Seoul, South Korea

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.